Searched for
AIOCD PHARMATRAC
Flu outbreak is tonic for medicine sales"Severe cough, cold, influenza infections led to the sale of medicines going up by 20-25% in February," said Rajiv Singhal, general secreta...- USV in talks with Novartis to buy Jalra Trademark for Rs. 200 CroreMumbai-based drugmaker USV Pvt Ltd is in advanced discussions to acquire the trademark for antidiabetes drug Jalra from Novartis for a deal...
- Our drug Ranitidine is safe: Strides PharmaRanitidine is a commonly prescribed medicine for countering acidity and is on the WHO’s Model List of Essential Medicines. In India, a host...
- GSK to recall Ranitidine from India after regulator alertBritish drugmaker will suspend release, distribution and supply of the heartburn drug.
- Natco dares Novartis with new heart drugAccording to data from AIOCD PharmaTrac, an agency that closely tracks pharmaceutical sales, Vymada had sales of Rs 68.3 crore for December...
- Government prohibits 328 fixed dose combinationsThe ban is effective immediately and may shave off over Rs 1,500 crore from India’s Rs 1.18 lakh crore pharmaceutical industry
- Health ministry to ban 328 combination medicines over safety concernsET has viewed parts of the latest ban notifications, which a senior ministry official confirmed would be notified this week.
- Supreme Court prescribes pain relief for 15 banned combination drugsThe order effectively brings several popular cough syrups, painkillers and cold medication out of the health ministry’s impending ban list,...
- Unichem Labs under regulator scanner for launching blood pressure medicines without price approvalAccording to NPPA, Unichem launched these medicines over four years before it applied to the regulator for price fixation.
- Biocon shares gains on cancer drug launchA biosimilar is a near copy of an original complex biologic drug.
- Popular antacid samples fail quality tests, company claims they were counterfeitsThe Pantocid and Pantocid DSR tested by CDSCO were not manufactured by Sun Pharma, the official spokesperson for the Mumbai-based drug make...
- Delhi High Court verdict on combination drugs ban likely todayEndlaw is expected to give his verdict even as the government has submitted a petition to transfer all FDC cases across the country to the ...
- Torrent Pharmaceuticals Shelcal 500 found substandard, Co claims it was counterfeitedThe entire batch was counterfeited by a third party which didn’t have the licence to manufacture this product, claimed the company in respo...
- Cipla aims to reach $1bn India sales through tie-upsCipla has stepped up launch plans in areas like respiratory, dermatology, cardiovascular and urology, which will help speed up its India gr...
- Abbott in trouble over death of a sales representativeThe incident sparked unrest among Abbott’s representatives, who staged demonstrations, demanding adequate compensation for the dead staff's...
- Dr Reddy's and NPPA battle at Delhi High Court over blood pressure drug's priceThe drug pricing watchdog's revision is unwarranted as the government is only supposed to take such action every five years, Dr Reddy’s cou...
- Novartis India shares jump over 17% on buyback planThe company’s shares closed at Rs 833 on the Bombay Stock Exchange. On May 18, the company had announced it would hold its board meeting on...
- Drugmakers launch cut-price versions of type 2 diabetes medicineDozens of Indian drugmakers have launched cut-price versions of teneligliptin, a new generation medicine for type 2 diabetes patients.
- Carlyle, Kedaara, others in talks to buy Cosme FarmaAdcock, which had acquired unlisted Cosme in 2012 for Rs 480 crore, has initiated the process of selling it, they said.
- Domestic drug market to grow by 13 per cent in 2013: ResearchThe 72,000-crore domestic drug market could grow between 11% and 13% in 2013, according to projections by pharma market research firms.
Load More
